Medicines Research in the UK: Terminal decline or new vistas?

07/07/2010 09:30 a.m. - 09:00 p.m.

Life Sciences and Life Sciences | Europe

Morrison & Foerster
One Ropemaker Street
London  EC2Y 9AW
United Kingdom


Lorna O'Neill
44 20 7920 4007

The Biopharma industries have had enormous societal impact during the past decades through the discovery and development of new medicines. The UK has played a leading role in this process and medicines research has been a strong driver of economic growth, a key provider of highly skilled employment and a key contributor to high quality healthcare.
However, the economic realities of the 21st century are forcing a reappraisal of previously successful business process and operating structures. With Big Pharma cutting research jobs and biotech companies finding it increasingly difficult to attract Venture funding, medicines research in the UK is in need of a new funding model in order to remain competitive.
This conference will consider the origins and potential consequences of this crisis, considering new models and approaches to reap the innovation dividend from the UK’s knowledge creation activities. In a sustainable world, wealth creation and social benefit can work hand in hand –to achieve greater value from intellectual property assets.
  • Paul Claydon, Partner, Morrison & Foerster, London
  • Julian Thurston, Partner, Morrison & Foerster, London

Email Disclaimer

Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.

©1996-2019 Morrison & Foerster LLP. All rights reserved.